Kairos Pharma, Ltd., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock and has a $12.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors surrounding the promising interim results from Kairos Pharma’s Phase 2 study of ENV-105. The study, which targets patients with metastatic castration-resistant prostate cancer (mCRPC), showed that the combination of ENV-105 and apalutamide led to a median progression-free survival (mPFS) exceeding 13 months, surpassing benchmarks from previous standard-of-care therapies. This significant improvement in mPFS indicates a strong potential for ENV-105 to extend treatment benefits without compromising patient quality of life.
Additionally, the favorable safety profile observed in the trial, with no dose-limiting toxicities or unexpected adverse events, supports the potential of ENV-105 as a viable treatment option. The study also demonstrated a reduction in PSA levels, further indicating clinical activity. Given the high prevalence of mCRPC and the limited treatment options available that do not increase toxicity, ENV-105’s ability to resensitize patients to AR inhibitor therapy is particularly noteworthy. These factors collectively contribute to Pantginis’s optimistic outlook on Kairos Pharma’s stock.
In another report released on September 18, Maxim Group also initiated coverage with a Buy rating on the stock with a $4.00 price target.